Cafepharma Today

June 20 2025 - Gene therapy faces fresh uncertainty as two more top FDA officials depart
Gene therapy faces fresh uncertainty as two more top FDA officials depart
Eli Lilly (LLY) sees strong demand for Mounjaro in India
A longer ‘winter’: Public funding slowdown heightens pressure on biotech startups
Is DTC pharma advertising coming to an end?
*please scroll down for all the latest news *

Make it like cafepharma, but for different industries. Learn more about CompanyUnderground

Check open job listings in your area
Click here to stay updated on CP happenings

learn about pharmaceutical fraud
learn about the False Claims Act
learn about clinical lab fraud

Current News

submit a press release

GSK kicks off Blenrep's market return with first myeloma combo nod in UK
Fierce Pharma
Thursday, April 17, 2025 - 11:04pm
tags:
GSK, Blenrep, UK, Multiple Myeloma
Stem cells to treat Parkinson's? 2 small studies hint at success
NPR
Thursday, April 17, 2025 - 10:54pm
tags:
Parkinson's Disease, stem cells, BlueRock Therapeutics, Bayer, clinical trials
Lilly Soars After Weight-Loss Pill Results Rival Ozempic’s
Yahoo/Bloomberg
Thursday, April 17, 2025 - 11:34am
tags:
Eli Lilly, clinical trials, obesity, orforglipron, Ozempic
J&J’s electrophysiology sales dip amid slow Varipulse start
Medtech Dive
Thursday, April 17, 2025 - 11:32am
tags:
JNJ, Medtech, PFA, Medtronic, Boston Scientific, earnings, Varipulse
BigHat Biosciences and Lilly Collaborate to Advance AI-Driven Antibody Therapeutics
Yahoo Finance
Thursday, April 17, 2025 - 11:28am
tags:
BigHat Biosciences, Eli Lilly, drug discovery, artificial intelligence, machine learning
CDC panel backs broader use of RSV shots
BioPharma Dive
Thursday, April 17, 2025 - 11:25am
tags:
CDC, ACIP, vaccines, RSV, GSK, Pfizer, Moderna Therapeutics
Mark Cuban’s drug firm targets injectable shortages
Beckers Hospital Review
Thursday, April 17, 2025 - 11:23am
tags:
Mark Cuban, Cost Plus Drugs, Morris & Dickson, injectables
Novartis scores NFL deal to tackle health outcomes
Pharma Voice
Thursday, April 17, 2025 - 11:22am
tags:
Novartis, pharma marketing, NFL
Bayer Unveils $44 Million Investment in Myerstown, PA Manufacturing Facility, Renewing Commitment to U.S. Innovation, Health and Community
Yahoo Finance
Thursday, April 17, 2025 - 11:21am
tags:
Bayer, innovation, Pennsylvania, consumer health, drug manufacturing
Sanofi pens $1.8B research deal for 2 bispecific antibodies aimed at autoimmune, immunology
Fierce Biotech
Thursday, April 17, 2025 - 11:08am
tags:
Sanofi, Earendil Labs, bispecific antibodies, ulcerative colitis, Crohn’s disease
Tariffs 'could cancel out discounts with biosimilars'
Pharmaphorum
Thursday, April 17, 2025 - 11:06am
tags:
biosimilars, Biosimilars Forum, tariffs
Glycomine raises $115m to advance rare disease therapy into Phase IIb
Clinical Trials Arena
Thursday, April 17, 2025 - 11:05am
tags:
Glycomine funding, GLM101, Rare Diseases
Sabin Vaccine Institute begins trial of vaccine candidate for Marburg virus disease
Clinical Trials Arena
Thursday, April 17, 2025 - 10:59am
tags:
Sabin Vaccine Institute, clinical trials, vaccines, Marburg virus
First meeting of CDC vaccine advisers under RFK Jr. is mostly 'business as usual'
NPR
Wednesday, April 16, 2025 - 11:07pm
tags:
CDC, ACIP, vaccines, RSV, COVID, chikungunya virus, Robert F Kennedy Jr.
White House looking to slash $40 billion from health department, Washington Post reports
Investing.com
Wednesday, April 16, 2025 - 11:03pm
tags:
Donald Trump, HHS
Trump throws pharma 'bread crumb' concession with call to end IRA pill penalty
Fierce Pharma
Wednesday, April 16, 2025 - 11:00pm
tags:
Donald Trump, tariffs
Allogene Granted Three U.S. FDA Fast Track Designations (FTD) for ALLO-329, a Next-Generation Dual-Targeted CD19/CD70 Allogeneic CAR T, for the Treatment of Lupus, Myositis and Scleroderma
Drugs.com
Wednesday, April 16, 2025 - 10:55pm
tags:
Allogene, FDA, CAR-T, fast track, ALLO-329, systemic lupus erythematosus, idiopathic inflammatory myopathy, diffuse systemic sclerosis
Hermes Intelligence Launches to Redefine Pharma Data Solutions
CP Wire
Wednesday, April 16, 2025 - 1:49pm
tags:
clinical trials, data, intelligence
Bluebird, after exploring 2nd buyout offer, sticks with Carlyle and SK Capital deal
Fierce Pharma
Wednesday, April 16, 2025 - 11:40am
tags:
Bluebird Bio, M&A, private equity, Carlyle, SK Capital
CDC advisers weigh lower age recommendation for RSV vaccines
Marketscreener
Wednesday, April 16, 2025 - 11:39am
tags:
CDC, ACIP, RSV, vaccines, GSK, Pfizer, Moderna Therapeutics

Pages

Latest CP Wire Articles

Hermes Intelligence Launches to Redefine Pharma Data Solutions [sponsored]
The Evolution of Medical Sales: What’s Changing in 2025?
FDA Scraps Key Vaccine Meetings—What It Means for Manufacturers
FDA approves Danziten, the first nilotinib treatment for Ph+ CML with no mealtime restrictions
Daily U.S. Flu Cases Expected to Nearly Double from Last Year by Late November, Predicts Novel Mathematical Forecasting Tool
PharmaBlock Receives 2024 ACS CMO Excellence in Green Chemistry Award, Marking a Second Consecutive Year of Recognition
Leading Clinical Research Network Centricity Research Acquires North Carolina-based Lucas Research
First-of-Its-Kind Alzheimer’s Disease Simulation Paves Way for Personalized Treatment: Penn State, Duke University Study
Centricity Research Appoints New CEO, CFO to Support Next Phase of Growth
Sermo Barometer Examines Influencers’ Impact on Patient Perceptions of Weight Loss Medications & Preventative Care Technologies

Latest Pharmagather Articles

Stir Bars Can't Be Ignored
In the Pipeline
AI Effects on Drug Patents
In the Pipeline
Mirror Morphine
In the Pipeline
Vaccine Advice, Vandalized
In the Pipeline
Novo Nordisk's Canadian Mistake
In the Pipeline
The Bethesda Declaration
In the Pipeline
Taurine and Aging: Is There Anything to It?
In the Pipeline
Cleaning Up the Medical Literature
In the Pipeline
Not One of Your Easy Crystals
In the Pipeline

current feelings about your job

Please rate how you feel about your job this moment. 1 = "I hate my job" and 7 = "I love my job"
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Fill in the blank.